Tilley Jefferson W
Roche Research Center, Nutley, NJ 07110, USA.
Expert Opin Ther Pat. 2009 Apr;19(4):549-53. doi: 10.1517/13543770902735824.
These two patent applications describe a subset of compounds previously claimed generically. Although both represent potentially exciting novel structural types, not previously associated with glucokinase activation, neither provides any relevant biological data to support their practical utility. Glucokinase activators from both Array Biopharma and Novo Nordisk (through their partner, Transtech Pharma) have entered the clinical development pipeline, but it is presently unknown whether the above patent applications cover any of these compounds.
这两项专利申请描述了先前笼统主张的一类化合物中的一个子集。尽管这两类化合物均代表了潜在的、令人兴奋的新型结构类型，且此前与葡萄糖激酶激活并无关联，但两者均未提供任何相关生物学数据来支持其实用性。Array生物制药公司和诺和诺德公司（通过其合作伙伴Transtech制药公司）的葡萄糖激酶激活剂均已进入临床开发流程，但目前尚不清楚上述专利申请是否涵盖了这些化合物中的任何一种。
